WHO Asks South African Startup To Replicate Moderna's mRNA Vaccine
The World Health Organization has hired the company, called Afrigen Biologics and Vaccines, as part of a $100 million plan to figure out how to make an mRNA vaccine against COVID that is as close as possible to the version produced by Moderna. Until recently, Afrigen specialized in developing veterinary vaccines using fairly traditional methods. Now, says Afrigen's managing director, Petro Treblanche, the company's labs are a hive of research into the cutting-edge technology behind mRNA vaccines. Once Afrigen has sorted out all the complicated steps to make Moderna's shot on an industrial scale, WHO and other partners plan to pay Afrigen to become a teaching center.
"We call it a 'technology transfer hub,' " says Martin Friede, the WHO official in charge of this effort. "Manufacturers from around the world will be invited to come and learn the entire process. So this will accelerate the availability of the technology, not to one manufacturer but to many manufacturers." Friede says it makes sense to set up more manufacturers of mRNA vaccines in particular because the technology appears so effective against COVID -- and because it shows promise against other diseases including malaria and tuberculosis. As to why WHO has chosen to try to copy Moderna rather than the other mRNA COVID vaccine, which is made by Pfizer BioNTech, Friede says the choice was practical. "Moderna has reiterated on several occasions that they will not enforce their intellectual property during the pandemic," says Friede. In other words, a manufacturer probably won't face a lawsuit for producing a vaccine that's virtually identical to Moderna's. Also, says Friede, compared to Pfizer's vaccine, there just happens to be a lot more information in the public domain about how Moderna's vaccine is made.
But Afrigen's Petro Treblanche says there are still a lot of unknowns. Take Moderna's patent. "It's written very carefully and cleverly to not disclose absolutely everything," says Treblanche. So while Afrigen has been able to determine most of the equipment and specialized ingredients that are needed, "what we don't know is the exact concentrations," says Treblanche. "And we don't know some of the mixing times -- some of the conditions of mixing and formulating." A particularly vexing question is how to replicate Moderna's "lipid nano-particle" -- a special casing around the mRNA strand at the heart of the vaccine that keeps it stable as it travels through the body to, as Treblanche puts it, "essential places like the spleen and lymph nodes." "We understand other encapsulations," says Treblanche. But for all the expertise at Afrigen, "my team has never formulated a liquid nanoparticle."
The World Health Organization has hired the company, called Afrigen Biologics and Vaccines, as part of a $100 million plan to figure out how to make an mRNA vaccine against COVID that is as close as possible to the version produced by Moderna. Until recently, Afrigen specialized in developing veterinary vaccines using fairly traditional methods. Now, says Afrigen's managing director, Petro Treblanche, the company's labs are a hive of research into the cutting-edge technology behind mRNA vaccines. Once Afrigen has sorted out all the complicated steps to make Moderna's shot on an industrial scale, WHO and other partners plan to pay Afrigen to become a teaching center.
"We call it a 'technology transfer hub,' " says Martin Friede, the WHO official in charge of this effort. "Manufacturers from around the world will be invited to come and learn the entire process. So this will accelerate the availability of the technology, not to one manufacturer but to many manufacturers." Friede says it makes sense to set up more manufacturers of mRNA vaccines in particular because the technology appears so effective against COVID -- and because it shows promise against other diseases including malaria and tuberculosis. As to why WHO has chosen to try to copy Moderna rather than the other mRNA COVID vaccine, which is made by Pfizer BioNTech, Friede says the choice was practical. "Moderna has reiterated on several occasions that they will not enforce their intellectual property during the pandemic," says Friede. In other words, a manufacturer probably won't face a lawsuit for producing a vaccine that's virtually identical to Moderna's. Also, says Friede, compared to Pfizer's vaccine, there just happens to be a lot more information in the public domain about how Moderna's vaccine is made.
But Afrigen's Petro Treblanche says there are still a lot of unknowns. Take Moderna's patent. "It's written very carefully and cleverly to not disclose absolutely everything," says Treblanche. So while Afrigen has been able to determine most of the equipment and specialized ingredients that are needed, "what we don't know is the exact concentrations," says Treblanche. "And we don't know some of the mixing times -- some of the conditions of mixing and formulating." A particularly vexing question is how to replicate Moderna's "lipid nano-particle" -- a special casing around the mRNA strand at the heart of the vaccine that keeps it stable as it travels through the body to, as Treblanche puts it, "essential places like the spleen and lymph nodes." "We understand other encapsulations," says Treblanche. But for all the expertise at Afrigen, "my team has never formulated a liquid nanoparticle."
